Usually, an antibody cocktail must be tailored for a specific cancer cell type based on its surface marker expressions, such as epithelial cell adhesion molecule (EpCAM) for epithelial cancers, human epithelial growth factor receptor 2 (HER2) for breast cancer and prostate specific membrane antigen (PSMA) for prostate cancer [32,34,55,56]. This evidence concerns the gene FOLH1 and breast cancer.